InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (8 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
8
T+90 hit rate
0%
T+90 mean return
-1.2%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Hambleton Julie, Director. Insider active across 4 companies, notably SpringWorks Therapeutics, Inc.. Aggregated, 18 reports have been published. Breakdown: 2 buys · 8 sells. Total volume traded: €822k. History available since 20 May 2021. The latest transaction was filed on 14 May 2025 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations18 total
10,060 shares0Common StockSEC:0001104659-25-049659:0
13,774 shares@ US$32.2762.3% of flowCommon StockSEC:0001104659-25-012362:0
15,132 shares@ US$1.394.6% of flowCommon StockSEC:0001415889-24-020266:0
2,946 shares@ US$39.413215.4% of flowCommon StockSEC:0001104659-24-068674:0
4,095 shares0Common StockSEC:0001104659-24-062979:0
2,418 shares@ US$29.31189.1% of flowCommon StockSEC:0001104659-23-083048:0
2,400 shares@ US$26.9188.5% of flowCommon StockSEC:0001104659-23-073743:0
4,648 shares0Common StockSEC:0001104659-23-064646:0
1,106 shares@ US$31.50214.7% of flowCommon StockSEC:0001104659-23-033345:0
4,818 shares0Common StockSEC:0001104659-22-063506:0
1,000 shares@ US$80.0017.1% of flowCommon StockSEC:0001209191-21-051011:0
1,000 shares@ US$80.0016.3% of flowCommon StockSEC:0001209191-21-051011
6,000 shares@ US$16.0050.0% of flowCommon StockSEC:0000899243-21-029053
Ideal exit: 16 Apr 2022 (T+270)
6,000 shares@ US$16.000.0026% mcap50.0% of flowCommon StockSEC:0000899243-21-029053:0
Ideal exit: 16 Apr 2022 (T+270)
2,000 shares@ US$80.0032.9% of flowCommon StockSEC:0001209191-21-038002:0
2,000 shares@ US$80.0031.4% of flowCommon StockSEC:0001209191-21-038002
1,106 shares0Common StockSEC:0001104659-21-070518
1,106 shares0Common StockSEC:0001104659-21-070518:0
18 of 18 declarations
About Hambleton Julie
Julie Hambleton is a Board Member at SpringWorks Therapeutics, Inc. and IGM Biosciences, Inc. She contributes to the governance of these biopharmaceutical companies by participating in strategic decision-making. Her experience in the biotechnology sector is valuable in guiding their development.
